You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru

    SBC: DFH Pharma, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Identification of potent and selective GLI1 inhibitors

    SBC: Zen-Bio, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast, colon, liver and ovarian cancers. Hh signaling is now implicated in approximately 20-25% of all can ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government